203 related articles for article (PubMed ID: 23208667)
1. Iron chelation therapy for a case of transfusion-independent MDS-RARS with significant iron overload.
Ohashi H; Arita K; Suzuki Y; Tomita A; Naoe T; Hattori A; Tatsumi Y; Kato K; Nagai H
Int J Hematol; 2013 Jan; 97(1):151-3. PubMed ID: 23208667
[No Abstract] [Full Text] [Related]
2. Iron overload in patients with myelodysplastic syndromes.
Jensen PD
Curr Hematol Malig Rep; 2007 Feb; 2(1):13-21. PubMed ID: 20425384
[TBL] [Abstract][Full Text] [Related]
3. Do Recent Randomized Trial Results Influence which Patients with Myelodysplastic Syndromes Receive Iron Chelation?
Gattermann N
Hematol Oncol Clin North Am; 2020 Apr; 34(2):465-473. PubMed ID: 32089223
[TBL] [Abstract][Full Text] [Related]
4. Iron overload in myelodysplastic syndromes.
Mahesh S; Ginzburg Y; Verma A
Leuk Lymphoma; 2008 Mar; 49(3):427-38. PubMed ID: 18297518
[TBL] [Abstract][Full Text] [Related]
5. Decision points in the treatment of transfusional iron overload in patients with myelodysplastic syndromes: why, when, and how to chelate.
Imran F; Phatak P
Expert Rev Hematol; 2017 Jan; 10(1):53-64. PubMed ID: 27923273
[TBL] [Abstract][Full Text] [Related]
6. [The role of iron metabolism in myelodysplastic syndromes].
Finelli C; Clissa C; Stanzani M
Recenti Prog Med; 2014 Mar; 105(3):123-6. PubMed ID: 24675455
[TBL] [Abstract][Full Text] [Related]
7. Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.
Gattermann N
Int J Hematol; 2008 Jul; 88(1):24-29. PubMed ID: 18581200
[TBL] [Abstract][Full Text] [Related]
8. Iron overload in myelodysplastic syndromes (MDS).
Gattermann N
Int J Hematol; 2018 Jan; 107(1):55-63. PubMed ID: 29177643
[TBL] [Abstract][Full Text] [Related]
9. Optimising management of deferasirox therapy for patients with transfusion-dependent thalassaemia and lower-risk myelodysplastic syndromes.
Kattamis A; Aydinok Y; Taher A
Eur J Haematol; 2018 Sep; 101(3):272-282. PubMed ID: 29904950
[TBL] [Abstract][Full Text] [Related]
10. Pathophysiological and clinical aspects of iron chelation therapy in MDS.
Gattermann N
Curr Pharm Des; 2012; 18(22):3222-34. PubMed ID: 22571702
[TBL] [Abstract][Full Text] [Related]
11. Iron chelation therapy in MDS: does it improve survival?
Leitch HA
Leuk Res; 2010 Jul; 34(7):852-3. PubMed ID: 20346508
[No Abstract] [Full Text] [Related]
12. A European survey on the detection and management of iron overload in transfusion-dependent patients with MDS.
Giagounidis A; Leto di Priolo S; Ille S; Fenaux P
Ann Hematol; 2011 Jun; 90(6):667-73. PubMed ID: 21327403
[TBL] [Abstract][Full Text] [Related]
13. To chelate or not to chelate in MDS: That is the question!
Zeidan AM; Griffiths EA
Blood Rev; 2018 Sep; 32(5):368-377. PubMed ID: 29602612
[TBL] [Abstract][Full Text] [Related]
14. Update of the GIMEMA MDS0306 study: Deferasirox for lower risk transfusion-dependent patients with myelodysplastic syndromes.
Piciocchi A; Sargentini V; Cotugno F; Bontempi K; Beltrami G; Di Tucci AA; Riva M; Quaresmini G; Vallisa D; Finelli C; Borin L; Fazi P; Vignetti M; Angelucci E
Eur J Haematol; 2019 May; 102(5):442-443. PubMed ID: 30776156
[No Abstract] [Full Text] [Related]
15. Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.
Gattermann N
Leuk Res; 2007 Dec; 31 Suppl 3():S10-5. PubMed ID: 18037413
[TBL] [Abstract][Full Text] [Related]
16. Iron overload in MDS-pathophysiology, diagnosis, and complications.
Gattermann N; Rachmilewitz EA
Ann Hematol; 2011 Jan; 90(1):1-10. PubMed ID: 20938663
[TBL] [Abstract][Full Text] [Related]
17. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
Angelucci E; Santini V; Di Tucci AA; Quaresmini G; Finelli C; Volpe A; Quarta G; Rivellini F; Sanpaolo G; Cilloni D; Salvi F; Caocci G; Molteni A; Vallisa D; Voso MT; Fenu S; Borin L; Latte G; Alimena G; Storti S; Piciocchi A; Fazi P; Vignetti M; Tura S
Eur J Haematol; 2014 Jun; 92(6):527-36. PubMed ID: 24580147
[TBL] [Abstract][Full Text] [Related]
18. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy.
Leitch HA
Leuk Res; 2007 Dec; 31 Suppl 3():S7-9. PubMed ID: 18037416
[TBL] [Abstract][Full Text] [Related]
19. NCCN Task Force: Transfusion and iron overload in patients with myelodysplastic syndromes.
Greenberg PL; Rigsby CK; Stone RM; Deeg HJ; Gore SD; Millenson MM; Nimer SD; O'Donnell MR; Shami PJ; Kumar R
J Natl Compr Canc Netw; 2009 Dec; 7 Suppl 9():S1-16. PubMed ID: 20064286
[TBL] [Abstract][Full Text] [Related]
20. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome.
Shenoy N; Vallumsetla N; Rachmilewitz E; Verma A; Ginzburg Y
Blood; 2014 Aug; 124(6):873-81. PubMed ID: 24923296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
